Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All curcumin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Curcumin and turmeric extract inhibited SARS-CoV-2 pseudovirus cell entry and Spike mediated cell fusion

Septisetyani et al., bioRxiv, doi:10.1101/2023.09.28.560070
Sep 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Curcumin for COVID-19
14th treatment shown to reduce risk in February 2021
 
*, now with p = 0.000000015 from 26 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19early.org
In Vitro study showing that curcumin inhibits SARS-CoV-2 pseudovirus cell entry and syncytia formation at 1-10μM in cells overexpressing ACE2 and TMPRSS2. Authors find that both curcumin and turmeric extract are potential inhibitors of SARS-CoV-2 infection at cell entry, with direct or indirect infection models.
43 preclinical studies support the efficacy of curcumin for COVID-19:
In Silico studies predict inhibition of SARS-CoV-2 with curcumin or metabolites via binding to the spikeA,17,9,20,11,4 (and specifically the receptor binding domainB,7,13,10), MproC,9,20,13,8,21,18,23,6,15,12,33,10,4, RNA-dependent RNA polymeraseD,19,10, ACE2E,11,12,14, nucleocapsidF,5,22, and nsp10G,22 proteins. In Vitro studies demonstrate inhibition of the spikeA,28 (and specifically the receptor binding domainB,36), MproC,33,35,28,16, ACE2E,36, and TMPRSS2H,36 proteins. In Vitro studies demonstrate efficacy in Calu-3I,34, A549J,28, 293TK,1, HEK293-hACE2L,26,16, 293T/hACE2/TMPRSS2M,27, Vero E6N,34,10,20,30,28,26,6,29,32, and SH-SY5YO,25 cells. Curcumin is predicted to inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain and the human ACE2 receptor for the delta and omicron variants7, decreases pro-inflammatory cytokines induced by SARS-CoV-2 in peripheral blood mononuclear cells32, and alleviates SARS-CoV-2 spike protein-induced mitochondrial membrane damage and oxidative stress1.
Septisetyani et al., 29 Sep 2023, preprint, 7 authors. Contact: enda041@brin.go.id.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperCurcuminAll
Curcumin and turmeric extract inhibited SARS-CoV-2 pseudovirus cell entry and Spike mediated cell fusion
Dr Endah Puji Puji Septisetyani, Dinda Lestari, Komang Alit Paramitasari, Pekik Wiji Prasetyaningrum, Ria Fajarwati Kastian, Adi Santoso, Kartini Eriani
doi:10.1101/2023.09.28.560070
Turmeric extract (TE) with curcumin as its main active ingredient has been studied as a potential COVID-19 therapeutic. Curcumin has been studied in silico and in vitro against a naive SARS-CoV-2 virus, yet little is known about TE's impact on SARS-CoV-2 infection. Moreover, no study reveals the potentials of both curcumin and TE on the inhibition of SARS-CoV-2 cell-to-cell transmission. Here, we investigated the effects of both curcumin and TE on the inhibition of SARS-CoV-2 entry and cell-to-cell transmission using pseudovirus (PSV) and syncytia models. We performed PSV entry assay in 293T or 293 cells expressing hACE2. The cells were pretreated with curcumin or TE, then treated with PSV with or without the test samples. Next, we carried out syncytia assay by co-transfecting 293T cells with plasmids encoding Spike, hACE2, and TMPRSS2 to be treated with the test samples. The results showed that in PSV entry assay on 293T/hACE/TMPRSS2 cells, both curcumin and TE inhibited PSV entry at concentrations of 1 µM and 10 µM for curcumin and 1 µg/ml and 10 µg/ml for TE. Moreover, both curcumin and TE also reduced syncytia formation compared to control cells. Based on our study, both TE and curcumin are potential inhibitors of SARS-CoV-2 infection at entry points, either by direct or indirect infection models.
CONFLICT OF INTEREST The authors declared no potential conflict of interests.
References
Bormann, Alt, Schipper, Van De Sand, Vtk et al., Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro, Viruses, doi:10.3390/v13101914
Buchrieser, Dufloo, Hubert, Monel, Planas et al., Syncytia formation by SARS-CoV-2-infected cells, The EMBO Journal, doi:10.15252/embj.2020106267
Chen, Chen, Wen, Ou, Chiou et al., Inhibition of Enveloped Viruses Infectivity by Curcumin, Plos One, doi:10.1371/journal.pone.0062482
Chen, Shien, Tiley, Chiou, Wang et al., Curcumin inhibits influenza virus infection and haemagglutination activity, Food Chemistry, doi:10.1016/j.foodchem.2009.09.011
Goc, Sumera, Rath, Niedzwiecki, Phenolic compounds disrupt spikemediated receptor-binding and entry of SARS-CoV-2 pseudo-virions, Plos One, doi:10.1371/journal.pone.0253489
Hirano, Murakami, COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome, Immunity, doi:10.1016/j.immuni.2020.04.003
Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell
Jackson, Farzan, Chen, Choe, Mechanisms of SARS-CoV-2 entry into cells, Nat Rev Mol Cell Biol, doi:10.1038/s41580-021-00418-x
Katopodis, Randeva, Spandidos, Saravi, Kyrou et al., Host cell entry mediators implicated in the cellular tropism of SARS-CoV-2, the pathophysiology of COVID-19 and the identification of microRNAs that can modulate the expression of these mediators (Review), Int J Mol Med, doi:10.3892/ijmm.2021.5075
Li, Pu, Lin, Liu, Zhao et al., Curcumin selectively induces colon cancer cell apoptosis and S cell cycle arrest by regulates Rb/E2F/p53 pathway, J. Mol. Struct, doi:10.1016/j.molstruc.2022.133180
Lin, Li, Wang, Shi, Syncytia formation during SARS-CoV-2 lung infection: a disastrous unity to eliminate lymphocytes, Cell Death Differ, doi:10.1038/s41418-021-00795-y
Marín-Palma, Tabares-Guevara, Zapata-Cardona, Flórez-Álvarez, Yepes et al., Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms, J Molecules, doi:10.3390/molecules26226900
Maurya, Kumar, Prasad, Bhatt, Saxena, Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor, Virusdisease, doi:10.1007/s13337-020-00598-8
Motohashi, Vanam, Gollapudi, In Silico Study of Curcumin and Folic Acid as Potent Inhibitors of Human Transmembrane Protease Serine 2 in the Treatment of COVID-19, INNOSC Theranostics and Pharmacological Sciences, doi:10.36922/itps.v3i2.935
Mounce, Cesaro, Carrau, Vallet, Vignuzzi, Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding, Antiviral Research, doi:10.1016/j.antiviral.2017.03.014
Pandamooz, Jurek, Meinung, Baharvand, As et al., Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments, Annu Rev Pharmacol Toxicol, doi:10.1146/annurev-pharmtox-121120-012309
Peng, Gao, Wu, Fan, Liu et al., Lung Organoids as Model to Study SARS-CoV-2 Infection, Cells, doi:10.3390/cells11172758
Rajah, Bernier, Buchrieser, Schwartz, The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation, Journal of Molecular Biology, doi:10.1016/j.jmb.2021.167280
Rajah, Hubert, Bishop, Saunders, Robinot et al., SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation, The EMBO Journal, doi:10.15252/embj.2021108944
Saccon, Chen, Mikaeloff, Rodriguez, Szekely et al., Cell-typeresolved quantitative proteomics map of interferon response against SARS-CoV-2, iScience, doi:10.1016/j.isci.2021.102420
Shanmugarajan, Prabitha, Kumar, Suresh, Curcumin to inhibit binding of spike glycoprotein to ACE2 receptors: computational modelling, simulations, and ADMET studies to explore curcuminoids against novel SARS-CoV-2 targets, RSC Adv, doi:10.1039/D0RA03167D
Sharifi-Rad, Rayess, Rizk, Sadaka, Zgheib et al., Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications, Front Pharmacol, doi:10.3389/fphar.2020.01021
Subbaiyan, Ravichandran, Singh, Sankar, Thomas et al., In silico Molecular Docking Analysis Targeting SARS-CoV-2 Spike Protein and Selected Herbal Constituents, J Pure Appl Microbiol, doi:10.22207/JPAM.14.SPL1
Tahmasebi, El-Esawi, Mahmoud, Timoshin, Valizadeh et al., Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients, J Cell Physiol, doi:10.1002/jcp.30233
Tomeh, Hadianamrei, Zhao, A Review of Curcumin and Its Derivatives as Anticancer Agents, Int. J. Mol. Sci, doi:10.3390/ijms20051033
Valizadeh, Abdolmohammadi-Vahid, Danshina, Ziya, Ammari et al., Nano-curcumin therapy, a promising method in modulating inflammatory preprint (which was not certified by peer review) is the author/funder
{ 'institution': [{'name': 'bioRxiv'}], 'indexed': {'date-parts': [[2023, 10, 1]], 'date-time': '2023-10-01T04:37:40Z', 'timestamp': 1696135060636}, 'posted': {'date-parts': [[2023, 9, 29]]}, 'group-title': 'Pharmacology and Toxicology', 'reference-count': 0, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2023, 9, 29]]}, 'abstract': '<jats:p>Turmeric extract (TE) with curcumin as its main active ingredient has been studied as ' 'a potential COVID-19 therapeutic. Curcumin has been studied in silico and in vitro against a ' "naive SARS-CoV-2 virus, yet little is known about TE's impact on SARS-CoV-2 infection. " 'Moreover, no study reveals the potentials of both curcumin and TE on the inhibition of ' 'SARS-CoV-2 cell-to-cell transmission. Here, we investigated the effects of both curcumin and ' 'TE on the inhibition of SARS-CoV-2 entry and cell-to-cell transmission using pseudovirus ' '(PSV) and syncytia models. We performed PSV entry assay in 293T or 293 cells expressing ' 'hACE2. The cells were pretreated with curcumin or TE, then treated with PSV with or without ' 'the test samples. Next, we carried out syncytia assay by co-transfecting 293T cells with ' 'plasmids encoding Spike, hACE2, and TMPRSS2 to be treated with the test samples. The results ' 'showed that in PSV entry assay on 293T/hACE/TMPRSS2 cells, both curcumin and TE inhibited PSV ' 'entry at concentrations of 1 lower case Greek muM and 10 lower case Greek muM for curcumin ' 'and 1 lower case Greek mug/ml and 10 lower case Greek mug/ml for TE. Moreover, both curcumin ' 'and TE also reduced syncytia formation compared to control cells. Based on our study, both TE ' 'and curcumin are potential inhibitors of SARS-CoV-2 infection at entry points, either by ' 'direct or indirect infection models. Keywords: COVID-19, curcumin, pseudovirus, SARS-CoV-2, ' 'syncytia, turmeric extract.</jats:p>', 'DOI': '10.1101/2023.09.28.560070', 'type': 'posted-content', 'created': {'date-parts': [[2023, 9, 30]], 'date-time': '2023-09-30T04:25:10Z', 'timestamp': 1696047910000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Curcumin and turmeric extract inhibited SARS-CoV-2 pseudovirus cell entry and Spike mediated ' 'cell fusion', 'prefix': '10.1101', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-6764-9686', 'authenticated-orcid': False, 'given': 'Endah Puji Puji', 'family': 'Septisetyani', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0009-0001-9293-4139', 'authenticated-orcid': False, 'given': 'Dinda', 'family': 'Lestari', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4054-3398', 'authenticated-orcid': False, 'given': 'Komang Alit', 'family': 'Paramitasari', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-6075-9850', 'authenticated-orcid': False, 'given': 'Pekik Wiji', 'family': 'Prasetyaningrum', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-3199-547X', 'authenticated-orcid': False, 'given': 'Ria Fajarwati', 'family': 'Kastian', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7105-8483', 'authenticated-orcid': False, 'given': 'Adi', 'family': 'Santoso', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9063-5944', 'authenticated-orcid': False, 'given': 'Kartini', 'family': 'Eriani', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2023.09.28.560070', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 30]], 'date-time': '2023-09-30T04:25:10Z', 'timestamp': 1696047910000}, 'score': 1, 'resource': {'primary': {'URL': 'http://biorxiv.org/lookup/doi/10.1101/2023.09.28.560070'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 9, 29]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1101/2023.09.28.560070', 'relation': {}, 'published': {'date-parts': [[2023, 9, 29]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit